ECG AI Gets FDA Nod

A standard 12-lead electrocardiogram is one of the oldest heart tests in medicine: 10 sticky sensors on the skin, a few seconds of recording, and a printout of the heart’s electrical pattern from 12 angles. Anumana just got United States Food and Drug Administration clearance to use that routine test for something doctors usually chase with much heavier workups: cardiac amyloidosis. (anumana.ai) Cardiac amyloidosis happens when misfolded proteins pile up inside the heart muscle the way starch can stiffen a shirt. Mayo Clinic says those deposits can keep organs from working normally, and when the heart is involved the muscle becomes thick and stiff instead of pumping and relaxing easily. (mayoclinic.org) (hopkinsmedicine.org) That disease is easy to miss because it can look like ordinary heart failure, shortness of breath, leg swelling, or an irregular heartbeat. The American Journal of Medicine reported diagnostic delays of up to 3 years from symptom onset, with some patients seeing more than 5 specialists before getting the right answer. (amjmed.com) Doctors usually do not confirm cardiac amyloidosis with an electrocardiogram alone. The current path often moves to blood and urine testing, echocardiography, magnetic resonance imaging, or a nuclear scan called a technetium-99m pyrophosphate scan, which uses a radioactive tracer to light up transthyretin amyloid in the heart. (asnc.org) (clevelandclinic.org) What Anumana built is software that looks for faint electrical fingerprints in the electrocardiogram that humans may not reliably spot by eye. The company said the cleared product is an artificial-intelligence software medical device designed to help clinicians identify patients who may be at risk for cardiac amyloidosis at the point of care. (anumana.ai) The regulatory detail matters here. Anumana said this cardiac amyloidosis tool had already received Breakthrough Device designation, and the Food and Drug Administration had included it among the first 15 devices in the Total Product Life Cycle Advisory Program pilot before this clearance arrived on April 8, 2026. (anumana.ai) This is not Anumana’s first cleared heart algorithm. Food and Drug Administration records show the company previously received a September 28, 2023 clearance for a low ejection fraction electrocardiogram algorithm, and a 2025 update expanded compatibility with more Philips PageWriter machines. (accessdata.fda.gov 1) (accessdata.fda.gov 2) The pattern across the industry is that artificial intelligence is moving from reading images to flagging disease from simpler signals. Food and Drug Administration records also show Ultromics received a November 15, 2024 clearance for EchoGo Amyloidosis, but that product is tied to echocardiography, while Anumana’s new clearance is for a standard 12-lead electrocardiogram. (accessdata.fda.gov) (anumana.ai) If this works in everyday clinics, the first effect may be a change in who gets referred, not an instant diagnosis on the spot. A cheap front-door test that flags more possible amyloidosis cases can send more patients toward confirmatory imaging and specialist clinics, especially because the American College of Cardiology says better noninvasive testing has already pushed awareness and earlier diagnosis higher. (acc.org) (clevelandclinic.org) The bigger bet is simple: if a disease that used to hide inside expensive scans can leave clues on a 10-second electrical tracing, hospitals can look for it far earlier and far more often. That is why a clearance tied to an old test matters more than it sounds, because it turns the electrocardiogram from a rhythm checker into a screening doorway for a disease many patients still reach too late. (anumana.ai) (amjmed.com)